Derek Barratt

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor

Vanessa Rodrik-Outmezguine, Masanori Okaniwa, Zhan Yao et al. · Nature · 2016 · 482 citations

Medicine, Pharmacology, Pharmacotherapy +11

Crystal Structure of Human MMP9 in Complex with a Reverse Hydroxamate Inhibitor

Siân Rowsell, Paul Hawtin, Claire A. Minshull et al. · Journal of Molecular Biology · 2002 · 257 citations

Life Sciences, Medicinal Chemistry, Pharmacology +9

Hydrogen bonding. Part 9. Solute proton donor and proton acceptor scales for use in drug design

Michael H. Abraham, Philip P. Duce, David V. Prior et al. · Journal of the Chemical Society Perkin Transactions 2 · 1989 · 234 citations

Natural Sciences, Chemistry, Medicinal Chemistry +17

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs

Jeffrey W. Johannes, Amber Balazs, Derek Barratt et al. · Journal of Medicinal Chemistry · 2021 · 140 citations · Full text

Life Sciences, Medicinal Chemistry, Oncology +13

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor

Frederick W. Goldberg, M. Raymond V. Finlay, Attilla Ting et al. · Journal of Medicinal Chemistry · 2019 · 79 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17